Blue Cross Blue Shield of Illinois Spravato Reimbursement Rates (2026)

Blue Cross Blue Shield of Illinois pays most psychiatrists $1,365.92 for an 84 mg Spravato session, about $76 more than the drug costs. Most psychiatric nurse practitioners get $1,161.03, about $129 less than the drug costs.

That gap decides whether a Spravato program pays. Blue Cross Blue Shield of Illinois pays for the drug inside its two session codes, not as a separate charge. So the session rate has to cover the drug, the visit and two hours of observation.

How Did We Read Blue Cross Blue Shield of Illinois’s Spravato Rates?

We read all ten of Blue Cross and Blue Shield of Illinois’s statewide network files for September 2026, 20 gigabytes of pricing data once unzipped. They cover its PPO, Blue Choice PPO, Blue Choice Preferred PPO, Blue Options, TraditionalBlue, MyBlue Plus, BlueCare Direct, HMO Illinois, Blue Advantage HMO and Blue Precision HMO networks.

We kept dollar rates labeled negotiated, billed as professional claims, for office visits. The office filter matters because the session codes pay $27 to $34 when billed from a facility, where the drug goes on the facility’s claim instead. We dropped rates set as a percentage of charges. We matched each provider ID number against the federal NPPES registry and kept individual psychiatrists, psychiatric nurse practitioners and clinical nurse specialists practicing in Illinois.

Blue Cross Blue Shield of Illinois Spravato Rates (2026 Table)

Rates extracted from Blue Cross and Blue Shield of Illinois’s September 2026 machine readable files, office setting, professional claims.

G2082 covers a session with up to 56 mg and G2083 a session with more than 56 mg. Each includes the visit, the drug and two hours of observation. The medians mix two pay levels, one for psychiatrists and one for nurse practitioners, explained below.

Does Blue Cross Blue Shield of Illinois Pay Separately for the Spravato Drug?

Almost never. Only 11 of the 2,567 Illinois prescribers with a G2083 rate also have a rate for J0013, the per-milligram drug code.

Three of them have a dollar rate of $16.11 per milligram. The other eight have J0013 priced at 50 percent of billed charges. For everyone else, the drug is paid only through G2082 and G2083. Build your numbers on those two codes.

Does Blue Cross Blue Shield of Illinois Pay Nurse Practitioners Less for Spravato?

Yes. Nurse practitioners get 85 percent of the psychiatrist rate for both session codes. Most prescribers sit on one of four standard amounts.

• Psychiatrists, main rate. $1,365.92 for G2083 and $960.42 for G2082. About 1,140 psychiatrists have it.
• Psychiatrists, lower rate. $1,241.65 for G2083 and $873.27 for G2082, held by about 260 psychiatrists.
• Nurse practitioners, main rate. $1,161.03 for G2083 and $816.36 for G2082. About 980 nurse practitioners have it.
• Nurse practitioners, lower rate. $1,055.40 for G2083 and $742.28 for G2082, held by about 355 nurse practitioners.

The lower rates are 91 percent of the main ones. Both levels appear in the same PPO files, so the network does not decide which one you get. It depends on the contract your practice bills under. A small group of contracts pays far more, up to $4,061.30 for G2083.

Does Buying Spravato Pay Under Blue Cross Blue Shield of Illinois?

Only on the psychiatrist main rate, and only by a little. An 84 mg dose is three nasal spray devices. At the national average drug acquisition cost (NADAC) published by Medicaid on October 7, 2026, that is about $1,290. A 56 mg dose is two devices, about $853.

• Psychiatrist main rate. G2083 leaves about $76 after the drug, and G2082 about $108.
• Psychiatrist lower rate. G2083 is about $48 short of the drug cost.
• Nurse practitioner main rate. G2083 is about $129 short, and G2082 about $36 short.
• Nurse practitioner lower rate. G2083 is about $235 short.

Even the best case is thin. The $76 has to pay for a clinician’s visit and two hours of monitored observation. Your own acquisition cost may also differ from the national average. A nurse practitioner led program that buys the drug loses money on every 84 mg session at these rates.

Does Blue Cross Blue Shield of Illinois Require Prior Authorization for Spravato?

Yes, for commercial non-HMO members since October 1, 2026, depending on the member’s plan. Blue Cross Blue Shield of Illinois’s specialty pharmacy prior authorization list added G2082, G2083 and J0013 on that date. The list says the requirement applies to “some” of those members, so check each patient’s plan. Before October, the codes sat on the medical policy code list, which recommended a review before treatment to avoid a review after the claim.

Its esketamine medical policy, RX501.105, sets the criteria. The version effective January 1, 2026 asks for less than the first version did in 2020.

• Treatment resistant depression. An adult with moderate or severe major depression, for example a PHQ-9 of 10 or more, who had an inadequate response to one antidepressant taken for at least six weeks. The 2020 version required two antidepressants from different classes and a PHQ-9 of 15.
• Approval length. Three months at first. Renewal needs measured improvement on a depression scale and no active substance use disorder.
• Depression with acute suicidal thoughts. 28 days, given together with an oral antidepressant.

We read the prior authorization list (updated October 2026) and the policy on October 13, 2026.

Can Blue Cross Blue Shield of Illinois Make Patients Try Other Drugs Before Spravato?

For treatment resistant depression, the policy asks for one antidepressant first. Illinois banned step therapy in 2026, but the ban leaves room for criteria like this.

The rule is 215 ILCS 134/87(f). From January 1, 2026, no utilization review program, policy or formulary “shall impose step therapy requirements.” It applies to mental health care, even though the rest of section 87 does not. It covers HMOs directly and fully insured PPO and other insurance plans through section 155.36 of the Insurance Code.

The ban has limits.

• Prior authorization. The law’s definition of step therapy leaves out prior authorization.
• Clinical review. It also leaves out review of whether a treatment is clinically appropriate under generally accepted standards. The policy lists the one antidepressant trial as part of qualifying for treatment resistant depression, not as a required order of drugs.
• Self-funded employer plans. These are outside the law and follow federal rules.

If a denial on a fully insured plan says the patient must first try a drug the policy does not require, cite section 87(f) in the appeal.

What This Means for Your Practice

Find your G2083 rate before you decide how to supply the drug. Your contract will sit on one of the four standard amounts or on a custom rate.

• On the psychiatrist main rate or higher. Buying the drug can work, but the margin covers little more than the visit. Track your real acquisition cost per device.
• On any lower rate. Each 84 mg session you buy loses money before staff time. Ask Blue Cross Blue Shield of Illinois whether the member’s plan lets a specialty pharmacy supply the drug, and which codes you then bill.

If your psychiatrists are on the 91 percent rate, you have a point to raise when you negotiate, since most psychiatrists in the same files get the main rate. Our guide to negotiating insurance contract rates covers how to ask.

Check prior authorization at the first visit, since commercial non-HMO plans can now require it. Our Blue Cross Blue Shield of Texas Spravato rates page shows how the same parent company prices Spravato in Texas. The therapy codes are in our Blue Cross Blue Shield of Illinois behavioral health rates page.

Disclaimer: This article uses rate information from the Machine Readable Files that Blue Cross and Blue Shield of Illinois publishes under the federal Transparency in Coverage rule. These files are posted to satisfy the regulation, not to be read. The files behind this analysis unpack to 20 gigabytes of raw pricing data, and Fuse built its own software to extract and verify the figures above. This analysis covers a single payer and will not reflect rates from all available insurance options in Illinois. Drug acquisition costs vary by practice and change often. Healthcare pricing and coverage policy change frequently, and individual circumstances affect actual payment. Practices should verify current rates and authorization requirements directly with Blue Cross and Blue Shield of Illinois before relying on them for billing or treatment decisions.